NVS250117P90000
- 0.16
- 0.000.00%
Novartis AG Newsroom
Novartis AG: Hold Rating Maintained Amid Legal Uncertainties and Limited Growth Prospects
Intra-Cellular Therapies Enters Settlement Agreement With Sandoz Resolving Patent Litigation Related To CAPLYTA Patent; No Terms Disclosed
Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ
Express News | Zhejiang Hisun Pharmaceutical: Everolimus tablets have obtained pharmaceutical registration certificates.
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)
'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Express News | The second phase of the Peking integrated circuit equipment industry investment and merger Fund has been established with a contribution of 2.5 billion.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Here's Why Novartis (NVS) Is a Strong Growth Stock
Novartis Reports Positive Results for Intrathecal Zolgensma
Novartis AG (NVS.US): Its new experimental drug improves motor functions in children with SMA.
Novartis AG stated that their new experimental drug improved motor function in children with spinal muscular atrophy (SMA) in a late-stage study.
Reported Earlier, Novartis Reports Topline Results From Phase III STEER Study; Study Met Its Primary Endpoint
Novartis Experimental Medicine Shows Improvement in Spinal Muscular Atrophy
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint
Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025